These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

85 related articles for article (PubMed ID: 8490845)

  • 1. Dose-related cutaneous toxicities with etoposide.
    Murphy CP; Harden EA; Herzig RH
    Cancer; 1993 May; 71(10):3153-5. PubMed ID: 8490845
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Phase I study of high-dose etoposide phosphate in man.
    Fields SZ; Budman DR; Young RR; Kreis W; Ingram R; Schulman P; Cherny RC; Wright J; Behr J; Snow C; Schacter LP
    Bone Marrow Transplant; 1996 Nov; 18(5):851-6. PubMed ID: 8932836
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Particular cutaneous side effects with etoposide-containing courses: is VP16 or etoposide phosphate responsible?
    Marigny K; Aubin F; Burgot G; Le Gall E; Gandemer V
    Cancer Chemother Pharmacol; 2005 Mar; 55(3):244-50. PubMed ID: 15526203
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Etoposide bioavailability after oral administration of the prodrug etoposide phosphate in cancer patients during a phase I study.
    Chabot GG; Armand JP; Terret C; de Forni M; Abigerges D; Winograd B; Igwemezie L; Schacter L; Kaul S; Ropers J; Bonnay M
    J Clin Oncol; 1996 Jul; 14(7):2020-30. PubMed ID: 8683232
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Two novel high-dose treatment regimens for metastatic breast cancer--ifosfamide, carboplatin, plus etoposide and mitoxantrone plus thiotepa: outcomes and toxicities.
    Fields KK; Elfenbein GJ; Perkins JB; Hiemenz JW; Janssen WE; Zorsky PE; Ballester OF; Kronish LE; Foody MC
    Semin Oncol; 1993 Oct; 20(5 Suppl 6):59-66. PubMed ID: 8211217
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose etoposide and marrow transplantation.
    Herzig RH
    Cancer; 1991 Jan; 67(1 Suppl):292-8. PubMed ID: 1984830
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Maximum-tolerated doses of ifosfamide, carboplatin, and etoposide given over 6 days followed by autologous stem-cell rescue: toxicity profile.
    Fields KK; Elfenbein GJ; Lazarus HM; Cooper BW; Perkins JB; Creger RJ; Ballester OF; Hiemenz JH; Janssen WE; Zorsky PE
    J Clin Oncol; 1995 Feb; 13(2):323-32. PubMed ID: 7844593
    [TBL] [Abstract][Full Text] [Related]  

  • 8. A phase I study of chronic daily dosing of oral etoposide in combination with cisplatin for patients with advanced cancer.
    Fukuoka M; Masuda N; Negoro S; Takada M; Kudoh S; Kusunoki Y; Matsui K; Takifuji N; Tachikawa A; Kawahara M
    Cancer; 1991 Jul; 68(2):284-8. PubMed ID: 2070326
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A phase I study of paclitaxel, etoposide, and cisplatin in extensive stage small cell lung cancer.
    Kelly K; Pan Z; Wood ME; Murphy J; Bunn PA
    Clin Cancer Res; 1999 Nov; 5(11):3419-24. PubMed ID: 10589753
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cutaneous adverse effects in patients treated with the multitargeted kinase inhibitors sorafenib and sunitinib.
    Lee WJ; Lee JL; Chang SE; Lee MW; Kang YK; Choi JH; Moon KC; Koh JK
    Br J Dermatol; 2009 Nov; 161(5):1045-51. PubMed ID: 19558553
    [TBL] [Abstract][Full Text] [Related]  

  • 11. A phase I study of etoposide phosphate administered as a daily 30-minute infusion for 5 days.
    Thompson DS; Greco A; Miller AA; Srinivas NR; Igwenezue KB; Hainsworth JD; Schacter LP; Kaul S; Barbhaiya RH; Garrow C
    Clin Pharmacol Ther; 1995 May; 57(5):499-507. PubMed ID: 7768072
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Cutaneous effects of thiotepa in pediatric patients receiving high-dose chemotherapy with autologous stem cell transplantation.
    Rosman IS; Lloyd BM; Hayashi RJ; Bayliss SJ
    J Am Acad Dermatol; 2008 Apr; 58(4):575-8. PubMed ID: 18249465
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Escalating sequential high-dose carboplatin and etoposide with autologous marrow support in children with relapsed solid tumors.
    Santana VM; Schell MJ; Williams R; Bowman LC; Thompson EI; Brenner MK; Mirro J
    Bone Marrow Transplant; 1992 Nov; 10(5):457-62. PubMed ID: 1464010
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Treatment of relapsed aggressive lymphomas: regimens with and without high-dose therapy and stem cell rescue.
    Hagemeister FB
    Cancer Chemother Pharmacol; 2002 May; 49 Suppl 1():S13-20. PubMed ID: 12042984
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Phase I Study of Etoposide and Cisplatin Chemotherapy Dose Escalation 
with Concurrent Twice-daily Radiotherapy for Patients 
with Limited-stage Small Cell Lung Cancer].
    You J; Yu H; Song M; Shi C; Wang X; Zheng Y; Yu R; Shi A; Zhu G
    Zhongguo Fei Ai Za Zhi; 2017 Jan; 20(1):55-60. PubMed ID: 28103974
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Phase I clinical and pharmacological study of 72-hour continuous infusion of etoposide in patients with advanced cancer.
    Bennett CL; Sinkule JA; Schilsky RL; Senekjian E; Choi KE
    Cancer Res; 1987 Apr; 47(7):1952-6. PubMed ID: 3815383
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Phase I evaluation of all-trans-retinoic acid in adults with solid tumors.
    Lee JS; Newman RA; Lippman SM; Huber MH; Minor T; Raber MN; Krakoff IH; Hong WK
    J Clin Oncol; 1993 May; 11(5):959-66. PubMed ID: 8487058
    [TBL] [Abstract][Full Text] [Related]  

  • 18. A phase I study of cisplatin, etoposide, and paclitaxel in small cell lung cancer.
    Bunn PA; Kelly K
    Semin Oncol; 1997 Aug; 24(4 Suppl 12):S12-144-S12-148. PubMed ID: 9331140
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A phase I study of dose-dense topotecan given upfront to standard therapy in patients with small cell lung cancer.
    Garst J; Herndon JE; Shafman T; Campagna L; Blackwell S; Padilla K; Bjurstrom T; Andrews C; Maravich-May D; Anderson E; Crawford J
    Clin Drug Investig; 2006; 26(5):257-66. PubMed ID: 17163259
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Phase I and II study of high-dose ifosfamide, carboplatin, and etoposide with autologous bone marrow rescue in lymphomas and solid tumors.
    Wilson WH; Jain V; Bryant G; Cowan KH; Carter C; Cottler-Fox M; Goldspiel B; Steinberg SM; Longo DL; Wittes RE
    J Clin Oncol; 1992 Nov; 10(11):1712-22. PubMed ID: 1403054
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.